Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Seventy-three patients with advanced non-Hodgkin lymphoma were treated with bleomycin, Adriamycin, cyclophosphamide, vincristine (Oncovin) and prednisone (BACOP), administered intensively during a 7-wk induction course followed by intermittent cycles every 3 wk for a total of 28 wk. The objective response in 44 evaluable nonleukemic patients with diffuse histology was 86%, with 66% achieving a complete remission (CR), varying from 80% for diffuse poorly differentiated lymphocytic (DPDL) to 56% for diffuse histiocytic (DH) lymphoma. In patients with nodular histology 89% (8/9) achieved a CR with a projected 75% of patiients in CR at 14 mo. Median follow-up from time of CR for nodular histology was 17 mo. The projected median duration of CR in diffuse histology was 14 mo. with median survival 14 mo. Patients with a partial response survived a median of 7 mo, compared to 3 mo for nonresponders. Of 29 patients with diffuse histology, 17 (59%) have remained disease free for 5-34 mo with a median follow-up of 12 mo. Survival beyond 20 mo has been projected for 42% of patients with diffuse histology (58% with DPDL and 32% with DH). The central nervous system (CNS) was involved in a total of 11/44 (25%) patients with diffuse histology, including 5 with primary CNS relapse. BACOP resulted in a higher CR rate and longer survival than a previous three-drug program (COP), especially in patients with diffuse histology.
 ...
PMID:Combination chemotherapy of advanced non-Hodgkin lymphoma with bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP). 6 57

The survey is introduced by references to the relations between special diagnostic findings and life expectancy. Also the contribution of the clinician to the diagnostics of the non-Hodgkin-lymphomas is dealt with. Five standpoints are to be regarded in the new management of chemotherapy: 1. The polychemotherapy is more effective than the monotherapy. 2. Massive-dose therapies of middle degree are more favourable than frequent, low-dosed cytostatic dosages. 3. Connection of the polychemotherapy with the radiotherapy in stage III and IV. 4. Particularly in the lymphomas with a high degree of malignancy polychemotherapy already in stage II following the radiation. 5. Especially intensive polychemotherapy in the lymphomas with a high degree of malignancy. The hitherto got findings in the polychemotherapy of the non-Hodgkin-lymphomas are reported. Here particularly the COP-scheme proved to be favourable, if necessary in connection with bleomycin, adriamycin or methotrexat; also BCNU or dakarbacin are possible. Own propositions, separated for lymphomas for low and high malignancy, respectively, take into consideration also the GDR-preparation Cytostasan.
 ...
PMID:[Therapy of non-Hodgkin lymphomas]. 9 97

Numerous examinations of the changes in B, T, null subpopulations were systematically carried out in 20 non Hodgkin lymphoma patients 8, 24, 48 hours after the therapy onset and subsequently at intervals of a few days during and after each chemotherapy cycle (COP, Knospe). T cells were evaluated by examining the receptor for neuraminidase pretreated sheep erythrocytes (nE), B lymphocytes by detecting surface immunoglobulins (SmIg) with normal and Fc deprived anti Fab2 globulin, moreover receptors for mouse erythrocytes (Em) and for C3 (EAC) were examined. A characteristic rise of the dominating subpopulation was observed during the first phase of the drug application which, most probably, was due to an expulsion of the pathological cells from involved lymphatic organs to the blood. On the basis of our clinical observations a conclusion has been drown, that this type of monitoring possibly renders a maximal effective treatment, enables the control of the accompanying immunosuppression and offers an additional criterion of the remission.
 ...
PMID:The monitoring of lymphocyte subpopulations in non Hodgkin lymphoma patients during chemotherapy. 31 89

The results of a chemotherapy regimen utilizing adriamycin in combination with vincristine, prednisone plus or minus cyclophosphamide (CHOP-HOP) for the treatment of non-Hodgkin lymphoma are compared to those of a non-adriamycin containing combination (COP). The complete remission (CR) rate of 67% for CHOP-HOP in malignant lymphoma, diffuse histiocytic type (MLDH) is superior to 33% obtained with COP. In malignant lymphoma, nodular poorly differentiated lymphocytic (MLNPD), the CR rate was: CHOP-HOP 83%, COP 44%. The prognostic factors for both treatment groups were compared and found to be similar. Thus, adriamycin appears to be responsible for this improvement in CR rate. When analyzed as a group, the patients treated with CHOP-HOP had a longer survival than those treated with COP. This difference was also evident in the subgroup of patients with MLDH. The smaller subgroup of patients with MLNPD treated with CHOP-HOP did not show a significant improvement in survival. A trend for longer duration of CR in both diffuse and nodular lymphomas was also observed, but this difference did not reach statistical significance possibly due to the smaller numbers of patients. Combination chemotherapy with adriamycin has resulted in a higher CR rate and survival for patients with non-Hodgkin lymphoma particularly for the subgroup of patients with MLDH.
 ...
PMID:Improvement in complete response rate, duration of response and survival with adriamycin combination chemotherapy for non-Hodgkin lymphoma: a prognostic factor comparison of two regimens. 36 84

Fourty-three of 61 patients suffering from low-grade malignant non-Hodgkin's lymphomas according to the Kiel classification were subjected to an intermittent combination chemotherapy with chlorambucil and prednisone. In 12 of 35 evaluable patients a complete remission, in 14 of 35 a partial remission could be achieved. The mean remission time of patients with a complete remission exceeds 16 months, that of patients with a partial remission amounts to more than 8 months. In 9 of 35 cases a remission could not be achieved. As 10 of the 12 patients in whom a complete remission could be obtained are alive, the median survival time in cases of complete remission cannot yet be determined. The hematological toxicity was very low, nausea and lack of appetite were observed in 9 of 35 patients. Three of 35 treated and evaluable patients died, viz., 1 patient with a centroblastic-centrocytic lymphoma and 1 patient with a chronic lymphocytic leukemia died from the sequelae of progression during the chemotherapy of second choice according to the COP regimen. The third patient with a centroblastic-centrocytic lymphoma died from the sequelae of an intrahepatic cholestatic icterus, also during the chemotherapy of second choice according to the COP regimen. In the last-mentioned case, autopsy also confirmed a continuous complete remission of the centroblastic-centrocytic lymphoma.
 ...
PMID:Intermittent combination chemotherapy with chlorambucil and prednisone of low-grade malignant non-Hodgkin's lymphomas according to the Kiel classification. 43 82

Gastro-intestinal involvement is a distinctive feature of non-Hodgkin's lymphomas. 31 cases are reported among 200 cases on NHL observed between 1960 and 1976. Multiple involvement appeared in 61%; a diffuse histological pattern is frequent (67%). The relapse of primary isolated gastro-intestinal localization (always) affected extra-digestive tissues (nodes, cavum). Chemotherapy is the mainstay of treatment COP, COAP and MOCA. Surgery is associated in localized involvement or in case of obstruction. High energy radiation therapy is indicated only in lymphosarcomas: -- to residual tumor after chemotherapy--in localized involvement diffuse on all the abdomen at 25 grays after surgery and a brief course of chemotherapy versus surgery and long course of chemotherapy alone.
 ...
PMID:[Gastro-intestinal involvement in non Hodgkin's lymphomas, 31 cases (author's transl)]. 60 Jul 22

The records of 360 patients with malignant lymphoma treated with various forms of combination chemotherapy from 1966 to 1974 were reviewed. A total of 181 infections was found in 125 patients. The most frequent types of infection were pneumonia (31%), skin infections (17%), urinary tract infections (13%) and septicemia (11%). An etiologic organism was was identified in 133 infections (73%). The most common causative organisms were bacteria (77%), especially gram-negative bacilli. Viral infections accounted for 18% of the infections with 21 of the 24 being due to herpes zoster. These were more frequently found in patients with Hodgkin's disease (14/21) than in the other lymphomas. Among patients with Hodgkin's disease, 53% treated with COP developed infections compared to only 27% treated with MOPP (p = 0.039). Among patients with non-Hodgkin's lymphoma, infections were more frequent in patients treated with Adriamycin containing combinations than with COP. Neutropenia (i.e. less than 1,000 neutrophils/mm3) was associated with 35% of infections in this study and was seen more often in patients with non-Hodgkin's lymphoma (p = 0.048).
 ...
PMID:Infections in patients with malignant lymphoma treated with combination chemotherapy. 91 45

86 patients with advanced malignant lymphomas (stage III and IV) were treated either with Vinblastine given as a single agent (49 cases) or with combination chemotherapy MOPP or COP (37 cases). In both, Hodgkin's disease and non-Hodgkin's lymphomas, induction of remission, relaps-free survival and prognostic significance of initial clinical stage were evaluated, in relation to the therapeutic modality. In patients with Hodgkin's disease, combination chemotherapy was found to produce significantly more durable remissions, when compared with single agent therapy. However, difference in the response rate, which was found to be more effective following the combination chemotherapy, was not statistically significant. In patients with non-Hodgkin's lymphomas overall lower response was recorded, regardless of the therapy applied. In all patients, better response rate and longer lasting remissions correlated with initial stage III.
 ...
PMID:Chemotherapy of advanced malignant lymphomas comparative evaluation of results with single agent and combination therapy. 95 33

Non-Hodgkin lymphomas belong to malignant hemopathies where clinical course, histological manifestation and therapy response are characterized by diverse features. Sensitivity of the lymphoma to chemotherapy introduced drug combinations for the improvement of patient survival rate and the prognosis. The study reviews the results achieved in 85 patients with NHL treated with different cytostatic combinations (COP, CHOP, COP-BLAM, MEV, LRS-074/B). The majority of the patients (41%) had entered the IV clinical stadium (Ann Arbor) with serious histological types of the disease (LDLL-45% and histiocytic 27%). This made us decide on LRS-074/B protocol (34%) and COP-BLAM cure (20%) planned for those with the advanced clinical stage and poor histological type of the disease. The full remission was achieved in 50%, partial in 28% of the cases while in 20% of the treated patients the therapy response lacked. Relapse of the disease occurs in about 50% of the treated patients. Patients treated with LRS-074/B protocol (p < 0.05) live statistically significantly longer. In a period of 24 months 50% of those treated with LRS-074/B protocol, COP and COP-BLAM cures show no symptoms. There is no a statistically significant difference regarding the mean survival rate (p > 0.05) in relation to the histological type of the disease.
 ...
PMID:[Effect of polychemotherapy in the treatment of patients with non-Hodgkin's lymphoma]. 136 55

Recombinant human granulocyte colony-stimulating factor (rhG-CSF) was given in combination with chemotherapy in elderly patients (greater than or equal to 65 years old) with malignant lymphoma, and the therapeutic efficacy and the incidence of side effects were determined. The subjects consisted of 5 males and 8 females with a median age of 74 years. One patient had Hodgkin's disease and 12 had non-Hodgkin's lymphoma. Regarding lymphoma stage, 2 were in stage II, 3 were in stage III, and 8 were in stage IV. The chemotherapy used was COP-BLAM in 8 patients, COP-BLAM III in 2, IMV-triple P in 2, and ACVP-16 in 1. Treatment with rhG-CSF (1.5 micrograms/kg/day) was commenced during or after the 2nd course of chemotherapy when the neutrophil count dropped to greater than or equal to 1,000/microliters, and was continued until the recovery of either the neutrophil or leukocyte count to 10,000/microliters or 20,000/microliters, respectively. The neutrophil nadir in the non-G-CSF group was 367.3 +/- 231.6/microliters. In the G-CSF group it was 754.6 +/- 116.4/microliters for the second course, with the difference between the 2 groups being significant (p less than or equal to 0.05). Also, the following time periods were significantly shorter in the G-CSF group than the non-G-CSF group: 1) the duration of a neutrophil count less than 1,000/microliters, 2) the duration of fever (greater than or equal to 37.5 degrees C), and 3) the time to recovery from the neutrophil nadir.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Clinical studies of recombinant human granulocyte colony-stimulating factor in elderly patients with malignant lymphoma]. 138 May 71


1 2 3 4 5 6 Next >>